Product Images Calcium Acetate

This is a table showing the adverse reactions in patients with end-stage renal disease undergoing hemodialysis. It reports the total number of adverse reactions for calcium acetate and placebo in a double-blind, placebo-controlled, cross-over study of liquid calcium. The preferred terms listed include nausea, vomiting, and hypercalcemia.*

Table 2 provides the average serum phosphorous and calcium levels at pre-study, interim, and study completion time points. The values are expressed in mg/dL. A total of ninety-one patients completed at least 6 weeks of the study. The mean and standard error (SE) values are expressed as Vsl. ANOVA test was conducted to check the difference in values at pre-study and study completion, and p-value®<0.001 for phosphorus, indicating a significant difference. For calcium, the p-value® was =0.001, which suggests no significant difference.*

The text describes Table 3 which shows the levels of serum phosphorous and calcium before and after each treatment arm. The values shown in mean = SEM format indicate that calcium acetate significantly affected the levels of phosphorus and calcium compared to the placebo. The table also includes a p-value obtained after applying ANOVA to the data.*

This is a medication called Calcium Acetate. It comes in a capsule form and the strength is 867mg. The bottle contains 30 capsules and is only available through a prescription. The lot number of the medication is 11401259 and it was packaged by DOH Central Pharmacy in Tallahassee, FL. The expiration date is August 30, 2014. There is also a package number/code provided (JPCH 331722377021).*